Cargando…

S150. DOPAMINE SYNTHESIS CAPACITY IN ANTIPSYCHOTIC NAïVE FIRST EPISODE PSYCHOTIC PATIENTS

BACKGROUND: Insufficient response to antipsychotics constitutes a challenge in the treatment of patients suffering from schizophrenia. Treatment resistances have been linked to a normal striatal dopamine system. We aim to stratify antipsychotic-naïve first-episode patients based on striatal dopamine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sigvard, Anne, Tangmose, Karen, Bojesen, Kirsten Borup, Jessen, Kasper, Nielsen, Mette Ødegaard, Fuglø, Dan, Jensen, Lars Thorbjørn, Rostrup, Egill, Glenthøj, Birte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888005/ http://dx.doi.org/10.1093/schbul/sby018.937

Ejemplares similares

F16. GLUTAMATE AND GABA LEVELS IN ANTIPSYCHOTIC-NAïVE SCHIZOPHRENIA PATIENTS ARE ASSOCIATED WITH TREATMENT OUTCOME AFTER 1.5 AND 6 MONTHS
por: Bojesen, Kirsten, et al.
Publicado: (2018)

S158. REWARD ALTERATIONS IN ANTIPSYCHOTIC NAïVE FIRST-EPISODE-PSYCHOSIS PATIENTS BEFORE AND AFTER TREATMENT WITH A PARTIAL DOPAMINE AGONIST
por: Tangmose, Karen, et al.
Publicado: (2018)

M143. REGIONAL CEREBRAL BLOOD FLOW IN INITIALLY ANTIPSYCHOTIC-NAïVE PATIENTS WITH SCHIZOPHRENIA OR PSYCHOSIS: EFFECTS OF PARTIAL D2 RECEPTOR AGONISM AND ASSOCIATION WITH SYMPTOM IMPROVEMENT
por: Bojesen, Kirsten, et al.
Publicado: (2020)

O6.3. ASSOCIATIONS BETWEEN COGNITIVE FUNCTION AND CORTICAL LEVELS OF GLUTAMATE AND GABA IN ANTIPSYCHOTIC-NAïVE PATIENTS WITH SCHIZOPHRENIA OR PSYCHOSIS
por: Bojesen, Kirsten, et al.
Publicado: (2020)

Dopamine Synthesis Capacity and GABA and Glutamate Levels Separate Antipsychotic-Naïve Patients With First-Episode Psychosis From Healthy Control Subjects in a Multimodal Prediction Model
por: Sigvard, Anne K., et al.
Publicado: (2022)

M148. NORMALIZATION IN REWARD PROCESSING DURING INITIAL TREATMENT MAY PREDICT LONG-TERM CLINICAL OUTCOME IN ANTIPSYCHOTIC NAïVE SCHIZOPHRENIA PATIENTS
por: Nielsen, Mette, et al.
Publicado: (2020)

Cerebral blood flow in striatum is increased by partial dopamine agonism in initially antipsychotic-naïve patients with psychosis
por: Bojesen, Kirsten Borup, et al.
Publicado: (2023)

O9.5. NORMALIZATION OF DISTURBANCES IN PREDICTION ERROR IS RELATED TO TREATMENT RESPONSE AND RELATED TO THALAMIC GLUTAMATE LEVELS IN NON-RESPONDERS
por: Tangmose, Karen, et al.
Publicado: (2020)

F176. CLINICAL CORRELATES OF CORTICAL STRUCTURE IN ANTIPSYCHOTIC-NAïVE SCHIZOPHRENIA PATIENTS BEFORE AND AFTER SIX-WEEK TREATMENT WITH A DOPAMINE D2/3 RECEPTOR ANTAGONIST
por: Jessen, Kasper, et al.
Publicado: (2018)

Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naïve Patients With Schizophrenia or Psychosis
por: Bojesen, Kirsten Borup, et al.
Publicado: (2021)

Treatment response after 6 and 26 weeks is related to baseline glutamate and GABA levels in antipsychotic-naïve patients with psychosis
por: Bojesen, Kirsten B., et al.
Publicado: (2020)

Alterations of Intrinsic Connectivity Networks in Antipsychotic-Naïve First-Episode Schizophrenia
por: Anhøj, Simon, et al.
Publicado: (2018)

S12. A MACHINE LEARNING FRAMEWORK FOR ROBUST AND RELIABLE PREDICTION OF SHORT- AND LONG-TERM CLINICAL RESPONSE IN INITIALLY ANTIPSYCHOTIC-NAïVE SCHIZOPHRENIA PATIENTS BASED ON MULTIMODAL NEUROPSYCHIATRIC DATA
por: Ambrosen, Karen S, et al.
Publicado: (2020)

Associations of neural processing of reward with posttraumatic stress disorder and secondary psychotic symptoms in trauma-affected refugees
por: Uldall, Sigurd Wiingaard, et al.
Publicado: (2020)

T231. QUALITY OF LIFE IN ANTIPSYCHOTIC-NAïVE YOUTH: EXPLORING THE INTERPLAY WITH METABOLIC SIDE-EFFECTS
por: Chintoh, Araba, et al.
Publicado: (2020)

Glutamate Levels and Resting Cerebral Blood Flow in Anterior Cingulate Cortex Are Associated at Rest and Immediately Following Infusion of S-Ketamine in Healthy Volunteers
por: Bojesen, Kirsten Borup, et al.
Publicado: (2018)

Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome
por: Wulff, Sanne, et al.
Publicado: (2015)

S57. TREATMENT SATISFACTION IN ACUTE PHASE PSYCHOSIS: COMPARISON BETWEEN ANTIPSYCHOTIC NAïVE AND PREVIOUSLY MEDICATED PATIENTS
por: Stabell, Lena, et al.
Publicado: (2018)

T14. HYPOTHALAMIC-PITUITARY-GONADAL AXIS HORMONES IN ANTIPSYCHOTIC NAïVE FIRST-EPISODE OF PSYCHOSIS AND HEALTHY CONTROLS
por: Teresa Pons-Cabrera, Maria, et al.
Publicado: (2020)

Accuracy of diagnostic classification algorithms using cognitive-, electrophysiological-, and neuroanatomical data in antipsychotic-naïve schizophrenia patients
por: Ebdrup, Bjørn H., et al.
Publicado: (2019)

Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits
por: Ebdrup, Bjørn H, et al.
Publicado: (2012)

Differential Effects of Aripiprazole and Amisulpride on Negative and Cognitive Symptoms in Patients With First-Episode Psychoses
por: Nielsen, Mette Ødegaard, et al.
Publicado: (2022)

O8.2. DURATION OF UNTREATED PSYCHOSIS (DUP) IS ASSOCIATED WITH WORSE RESPONSE TO TREATMENT IN ANTIPSYCHOTIC NAïVE FIRST EPISODE PSYCHOSIS
por: Cavalcante, Daniel, et al.
Publicado: (2018)

T154. WHITE MATTER INTEGRITY, DURATION OF UNTREATED PSYCHOSIS, AND ANTIPSYCHOTIC TREATMENT RESPONSE IN MEDICATION-NAïVE FIRST EPISODE PSYCHOSIS PATIENTS
por: Kraguljac, Nina, et al.
Publicado: (2020)

T119. NO DIFFERENCE BETWEEN VOLITIVE AND EXPRESSIVE NEGATIVE SYMPTOMS FOR EARLY TREATMENT RESPONSE IN FIRST EPISODE OF PSYCHOSIS ANTIPSYCHOTIC NAïVE PATIENTS
por: Haguiara, Bernardo, et al.
Publicado: (2020)

Reward Processing as an Indicator of Vulnerability or Compensatory Resilience in Psychoses? Results From a Twin Study
por: Nielsen, Mette Ødegaard, et al.
Publicado: (2022)

S250. RELATION BETWEEN PSYCHOPATHOLOGY AND QUALITY OF LIFE IN SCHIZOPHRENIA PATIENTS BEFORE AND AFTER FIRST ANTIPSYCHOTIC TREATMENT
por: Andersen, Gitte, et al.
Publicado: (2018)

T165. ULTRA-HIGH FIELD MORPHOMETRY IN DRUG-NAïVE FIRST EPISODE PSYCHOSIS
por: Das, Tushar, et al.
Publicado: (2018)

Striatal Volume Increase After Six Weeks of Selective Dopamine D(2/3) Receptor Blockade in First-Episode, Antipsychotic-Naïve Schizophrenia Patients
por: Andersen, Helle G., et al.
Publicado: (2020)

T16. GLUTAMATERGIC CHANGES IN UHR
por: Wenneberg, Christina, et al.
Publicado: (2018)

Frontal D(2/3) Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology
por: Nørbak-Emig, Henrik, et al.
Publicado: (2016)

Concurrent functional magnetic resonance imaging and electroencephalography assessment of sensory gating in schizophrenia
por: Bak, Nikolaj, et al.
Publicado: (2013)

F181. CHANGE IN PREFRONTAL-LIMBIC MORPHOLOGY AND COGNITION IN DRUG-NAïVE FIRST-EPISODE PSYCHOSIS PATIENTS FOLLOWING ATYPICAL ANTIPSYCHOTIC TREATMENT: A BRIEF LONGITUDINAL STUDY
por: Woodward, Melissa, et al.
Publicado: (2018)

T164. STRUCTURAL COVARIANCE IN DRUG-NAïVE FIRST EPISODE PSYCHOSIS: AN ULTRA-HIGH FIELD MRI STUDY
por: Das, Tushar, et al.
Publicado: (2018)

O6.3. PATTERNS OF GRAY MATTER ABNORMALITIES IN PATIENTS WITH FIRST-EPISODE AND TREATMENT-NAïVE SCHIZOPHRENIA
por: Li, Mingli, et al.
Publicado: (2018)

O3.3. REWARD PROCESSING AS A VULNERABILITY INDICATOR FOR PSYCHOSIS: RESULTS FROM A TWIN STUDY
por: Nielsen, Mette, et al.
Publicado: (2018)

The impact of schizophrenia and intelligence on the relationship between age and brain volume
por: Jensen, Maria H., et al.
Publicado: (2018)

Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist—protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol
por: Ishøy, Pelle L, et al.
Publicado: (2014)

S6. SLEEP ENDOPHENOTYPES OF SCHIZOPHRENIA: A HIGH-DENSITY EEG STUDY IN DRUG-NAïVE, FIRST EPISODE PSYCHOSIS PATIENTS
por: Castelnovo, Anna, et al.
Publicado: (2020)

T121. BLUNTED AFFECT EARLY PROGRESSION IN DRUG-NAïVE FIRST EPISODE SCHIZOPHRENIA PATIENTS: 10-WEEK FOLLOW UP
por: Kagan, Simão, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_34qqha0kosaave03b86tf0dsn2